August 30, 2018
Science Magazine (August 30, 2018): The Alzheimer’s Gamble: NIH Tries to Turn Billions in New Funding into Treatment for Deadly Brain Disease
When molecular biologist Darren Baker was winding up his postdoc studying cancer and aging a few years ago at the Mayo Clinic in Rochester, Minnesota, he faced dispiritingly low odds of winning a National Cancer Institute grant to launch his own lab. A seemingly unlikely area, however, beckoned: Alzheimer's disease. The U.S. government had begun to ramp up research spending on the neurodegenerative condition, which is the sixth-leading cause of death in the United States and will afflict an estimated 14 million people in this country by 2050.
August 22, 2018
New York Times (August 22, 2018): Fighting Dementia With Memories of Childhood and Happy Times
“We’re lost,” said Truus Ooms, 81, to her friend Annie Arendsen, 83, as they rode a city bus together.
“As the driver, you should really know where we are,” Ms. Arendsen told Rudi ten Brink, 63, who sat at the wheel of the bus.
But she was joking.
August 16, 2018
Boston Globe (August 13, 2018): A Landmark Law Hopes to Improve Alzheimer’s Care in Mass.
Rhiana Kohl has faced many sad surprises in the seven years since her husband, Alfredo Bartolozzi, first showed symptoms of Alzheimer’s disease. But perhaps the biggest shock was finding out that even health care workers often don’t understand this common illness.
During a hospital stay, an X-ray technician didn’t grasp that Bartolozzi couldn’t follow directions. In an emergency room visit, staffers asked factual questions of a stricken man who didn’t know where he was.
August 1, 2018
Harvard Gazette (July 31, 2018): ‘Alzheimer’s in a Dish’ Model Provides Answers
Building on their development of the first culture system to replicate fully the pathology behind Alzheimer’s disease, a Massachusetts General Hospital (MGH) research team has now produced a system that includes neuroinflammation, the key biological response that leads to the death of brain cells. The investigators describe their system, which incorporates the glial cells that that not only surround and support neurons but also provide some immune system functions, in a paper published in Nature Neuroscience.
July 30, 2018
CNN News (July 30, 2018): Borrowing from the Cancer Playbook to Find Treatment for Alzheimer's Disease
It's been notoriously difficult to develop medicines for Alzheimer's disease, the sixth leading cause of death in the United States. Each year, it seems, pharmaceutical companies release data from studies of promising drug candidates that merit only a collective sigh of disappointment.
In search of fresh ideas, researchers have begun to borrow a phrase or two from the more familiar language of cancer treatment.
July 26, 2018
The New York Times (July 25, 2018): New Alzheimer’s Drug Shows Big Promise in Early Trial Results
An exciting update on the race to end Alzheimer's disease: in a clinical trial, a new drug reduced amyloid plaques and improved cognitive function -- the first time a drug has had both effects. Dr. Reisa Sperling of the MADRC, quoted in the The New York Times, said, "I don't know if we've hit a home run yet. It's important not to over-conclude on the data. But as a proof of concept, I feel like this is very encouraging." To read the article in its entirety, click here.
July 26, 2018
Alzheimer's Association (July 25, 2018): Study Shows Intensive Blood Pressure Control Reduces Risk of Mild Cognitive Impairment (MCI) & the Combined Risk of MCI and Dementia
Significant reductions in the risk of mild cognitive impairment (MCI)*, and the combination of MCI and dementia**, have been shown for the first time through aggressive lowering of systolic blood pressure in new research results from the federally-funded SPRINT MIND Study reported at the Alzheimer’s Association International Conference (AAIC) 2018 in Chicago.
July 24, 2018
PR NewsWire (July 23, 2018): New National Strategy For Recruitment And Participation In Alzheimer's Disease Clinical Trials Takes Shape
Increased public and private investments in Alzheimer's disease research have brought about a proliferation of potential therapeutic targets. Drugs and other interventions to hit those targets are moving into clinical trials. Other studies are helping us better understand risks for dementia and examining best approaches to clinical and long-term care. Yet engagement and participation has not kept pace with the acceleration of research and great need for volunteers.
July 24, 2018
Denver Post (July 23, 2018): Women’s Reproductive History May Predict Alzheimer’s Risk
When asking why more women than men have Alzheimer’s disease or dementia – nearly two-thirds of Americans with the disease are women – the prevailing explanation has been that women live longer and that it is a disease associated with aging.
July 23, 2018
CNBC (July 22, 2018): Top Alzheimer’s Researchers Hope that Near-100 Dementia Drugs in Trials are Moving Closer to a Breakthrough
The search for an Alzheimer’s disease cure has been dogged by pharmaceutical failures, but a network of the world’s top dementia scientists released a report on Sunday saying that the number of drugs making it to phase two and phase three of clinical trials encourages them to believe that a blockbuster may be among compounds in the current development pipeline.
Pages
